Oxalic Acid

Oxalic Acid

SCHEMBL4772211

CCNS(=O)(=O)c1ccc(-c2cc3ccccc3c(N3CCN(CCO)CC3)n2)cc1.O=C(O)C(=O)O

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
HTR7 P34969 12/20 0.44
DRD2 P14416 11/20 0.44
HTR2A P28223 11/20 0.44
HTR6 P50406 11/20 0.44
HTT P42858 1/20 0.42
HTR1A P08908 2/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
BACE1 P56817 1/20 0.40
POLB P06746 1/20 0.40
SYK P43405 1/20 0.40
PHGDH O43175 1/20 0.40
GBA1 P04062 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767462 0.96 DRD2 (0.47) KDM4EALDH1A1LMNAHTR7DRD2
Oxalic Acid SCHEMBL4765127 0.89 KDM4E (0.46) KDM4EALDH1A1LMNAHTR7DRD2
SCHEMBL4771141 0.87 GBA1 (0.43) LMNAHTR7DRD2HTR2AHTR6
SCHEMBL4772217 0.87 HTR7 (0.42) HTR7DRD2HTR2AHTR6HTR1A
Hydrochloric Acid SCHEMBL4770876 0.86 GBA1 (0.43) LMNAHTR7DRD2HTR2AHTR6
SCHEMBL4768837 0.84 RXFP1 (0.45) KDM4EALDH1A1LMNAHTR7DRD2
SCHEMBL4770341 0.84 DRD2 (0.47) LMNAHTR7DRD2HTR2AHTR6
Hydrochloric Acid SCHEMBL4766031 0.83 DRD2 (0.46) LMNAHTR7DRD2HTR2AHTR6
SCHEMBL4774328 0.82 GBA1 (0.43) KDM4EALDH1A1HTR7DRD2HTR2A
SCHEMBL4775898 0.82 MEN1 (0.43) KDM4EALDH1A1LMNAHTR7DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 KDM4E 1058/4885ALDH1A1 1071/4885LMNA 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.